trial · primary record
Felzartamab
Graves' Disease
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2028-03-31 |
| Primary endpoint | Percentage of Participants who are Euthyroid and off Anti-Thyroid Drugs (ATD) at Week 24 |
| Registry ID | NCT07722546 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:49.646Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07722546
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.